Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:

Xbiome Acquires Global Rights to Microbiome Product for Ulcerative Colitis

publication date: Apr 28, 2022

Xbiome acquired global rights to a clinical-stage microbiome candidate for mild to moderate ulcerative colitis from Assembly Biosciences of South San Francisco. M201 is comprised of commensal bacteria that are known to modulate ulcerative colitis-relevant cellular mechanisms in human cell-based assays and animal models. Xbiome was previously headquartered in Shenzhen. It has moved its headquarters and an R&D lab to Cambridge, MA, though it continues to have operations in Beijing and Shenzhen. In late 2021, Xbiome completed a $100 million funding from China investors. More details....

Share this with colleagues:  

This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio Event
Singapore and Digital
April 26-27, 2023
ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China